Tumor-treating fields with immunotherapy and chemo for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bile duct cancer or gallbladder cancer that cannot be removed with surgery.
- You should not have received chemotherapy for advanced disease before (unless it was more than 6 months after surgery or after finishing adjuvant therapy).
- You need to be able to take care of yourself and do light activities (not bedridden).
- You must be between 18 and 75 years old and weigh more than 30 kg (66 lbs).
- You cannot have certain medical conditions, like an active autoimmune disorder, implanted medical devices (e.g., pacemaker, metal in chest/abdomen), or active infections (e.g., HIV, tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
This trial tests a combination of radiation therapy (SBRT), two chemotherapy drugs (gemcitabine and cisplatin), and an immunotherapy drug (sintilimab) as a first-line treatment for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
Hear when a new Biliary Tract Cancers (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.